An inflammatory liquid fingerprint predicting tumor recurrence after liver transplantation for hepatocellular carcinoma
Tumor recurrence is a life-threatening complication after liver transplantation (LT) for hepatocellular carcinoma (HCC). Precise recurrence risk stratification before transplantation is essential for the management of recipients. Here, we aimed to establish an inflammation-related prediction model for posttransplant HCC recurrence based on pretransplant peripheral cytokine profiling. Two hundred and ninety-three patients who underwent LT in two independent medical centers were enrolled, and their pretransplant plasma samples were sent for cytokine profiling. We identified four independent risk factors, including alpha-fetoprotein, systemic immune-inflammation index, interleukin 6, and osteocalcin in the training cohort (<i>n</i> = 190) by COX regression analysis. A prediction model named inflammatory fingerprint (IFP) was established based on the above factors. The IFP effectively predicted posttransplant recurrence (area under the receiver operating characteristic curve [AUROC]: 0.792, C-index: 0.736). The high IFP group recipients had significantly worse 3-year recurrence-free survival rates (37.9 vs. 86.9%, <i>p</i> < 0.001). Simultaneous T-cell profiling revealed that recipients with high IFP were characterized by impaired T cell function. The IFP also performed well in the validation cohort (<i>n</i> = 103, AUROC: 0.807, C-index: 0.681). In conclusion, the IFP efficiently predicted posttransplant HCC recurrence and helped to refine pretransplant risk stratification. Impaired T cell function might be the intrinsic mechanism for the high recurrence risk of recipients in the high IFP group.
Authors
- Huigang Li (ORCID: https://orcid.org/0000-0002-5575-8068)
- Xiao Xu (ORCID: https://orcid.org/0000-0002-2761-2811)
- Modan Yang (ORCID: https://orcid.org/0009-0005-4983-2224)
- Zuyuan Lin
- Zhe Yang (ORCID: https://orcid.org/0000-0001-9525-035X)
- Renyi Su (ORCID: https://orcid.org/0000-0001-9577-7012)
- Qinfen Xie
- Zhihang Hu
- Junli Chen (ORCID: https://orcid.org/0000-0002-0542-9709)
- Xuyong Wei (ORCID: https://orcid.org/0000-0001-8755-5268)
- Jianyong Zhuo
- Linhui Pan
- Wei Feng Shen (ORCID: https://orcid.org/0000-0002-7093-2001)
- Siyi Dong
- Hao Chen (ORCID: https://orcid.org/0009-0001-6480-7976)
- Li Zhuang (ORCID: https://orcid.org/0000-0002-2487-463X)
- Rui Wang (ORCID: https://orcid.org/0000-0002-9852-1247)
- Shusen Zheng (ORCID: https://orcid.org/0000-0003-1459-8261)
- Xinyu Yang (ORCID: https://orcid.org/0000-0001-5129-8781)
- Di Lu (ORCID: https://orcid.org/0000-0002-8724-3739)
- Junjie Yin
- Chiyu He
Institutions
- Westlake University (CN)
- Zero to Three (US)
- Zhejiang Provincial People's Hospital (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- Hangzhou Red Cross Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Hangzhou Medical College (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- MedComm
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1002/mco2.678
- Citations
- 4
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 1.14
Funders
- National Natural Science Foundation of China
- Major Research Plan
- National Key Research and Development Program of China